• 81
  • 5
  • Favorite

J&J reports promising Ebola vaccine data

Reuters2021-09-14

Sept 13 (Reuters) - Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.

The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants, the company said, citing data from a late-stage trial.

The regimen, Zabdeno and Mvabea, generated immune responses that persisted in adults for at least two years.

J&J added that there were no safety signals of concern.

"These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin," J&J's Chief Scientific Officer Paul Stoffels said.

The company added that a booster shot administered two years after the initial vaccination induced a strong immune response within seven days.

Ebola typically kills about half of those it infects, although vaccines and new treatments have proven highly effective in reducing fatality rates.

Last month, the World Health Organisation warned that on top of the COVID-19 pandemic, West Africa is facing new outbreaks of the viral haemorrhagic fevers Marburg and Ebola, risking huge strains on ill-equipped health systems.

J&J's vaccine regimen had received European approval in July 2020 and prequalification from the WHO, which allows medicines to be procured by developing countries, in April 2021.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment5

  • SSVC
    ·2021-09-14
    Ok Appreciate your comments and response Thanks 
    Reply
    Report
  • rossannathom
    ·2021-09-14
    That’s great news, we need to save more people 
    Reply
    Report
  • J1000
    ·2021-09-14
    Thanks 
    Reply
    Report
    Fold Replies
    • J1000
      ThAnks
      2021-09-14
      Reply
      Report
  • ASMH
    ·2021-09-14
    Like 
    Reply
    Report
    Fold Replies
    • ASMH
      Like
      2021-09-17
      Reply
      Report
    • chowtimeee
      hopeful
      2021-09-14
      Reply
      Report
    • Leonardtan
      Sdgg
      2021-09-14
      Reply
      Report
  • ivy888
    ·2021-09-14
    Like 
    Reply
    Report
    Fold Replies
    • Syww
      [Strong][Strong]
      2021-09-14
      Reply
      Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial